WallStreetZenWallStreetZen

NASDAQ: NAMS
Newamsterdam Pharma Co Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NAMS

Based on 6 analysts offering 12 month price targets for Newamsterdam Pharma Co Nv

Min Forecast
$27.00+7.7%
Avg Forecast
$40.67+62.21%
Max Forecast
$52.00+107.42%

Should I buy or sell NAMS stock?

Based on 6 analysts offering ratings for Newamsterdam Pharma Co Nv.

Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NAMS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NAMS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NAMS stock forecasts and price targets.

NAMS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-07
lockedlocked$00.00+00.00%2025-07-17
lockedlocked$00.00+00.00%2025-06-17
lockedlocked$00.00+00.00%2025-06-12
lockedlocked$00.00+00.00%2025-06-10
ScotiaBank
Bottom 5%
5
BuyMaintains$52.00+107.42%2025-02-27

1 of 1

Forecast return on equity

Is NAMS forecast to generate an efficient return?

Company
-9.66%
Industry
125.25%
Market
-47.51%
NAMS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NAMS forecast to generate an efficient return on assets?

Company
-9.23%
Industry
47.65%
NAMS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NAMS earnings per share forecast

What is NAMS's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.47
Avg 2 year Forecast
-$2.06
Avg 3 year Forecast
-$1.67

NAMS revenue forecast

What is NAMS's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$25.2M-66.5%
Avg 2 year Forecast
$360.0k-99.52%
Avg 3 year Forecast
$126.5M+68.01%
NAMS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NAMS revenue growth forecast

How is NAMS forecast to perform vs Biotechnology companies and vs the US market?

Company
15.75%
Industry
79.5%
Market
10.92%
NAMS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NAMS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NAMS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NAMS$25.07$40.67+62.21%Buy
ARWR$20.51$48.75+137.69%Buy
RARE$29.69$83.91+182.62%Strong Buy
CRNX$30.72$75.67+146.31%Strong Buy
XENE$38.23$51.88+35.69%Strong Buy
View Top Biotech Stocks

Newamsterdam Pharma Co Nv Stock Forecast FAQ

Is Newamsterdam Pharma Co Nv Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: NAMS) stock is to Buy NAMS stock.

Out of 6 analysts, 2 (33.33%) are recommending NAMS as a Strong Buy, 3 (50%) are recommending NAMS as a Buy, 1 (16.67%) are recommending NAMS as a Hold, 0 (0%) are recommending NAMS as a Sell, and 0 (0%) are recommending NAMS as a Strong Sell.

If you're new to stock investing, here's how to buy Newamsterdam Pharma Co Nv stock.

What is NAMS's earnings growth forecast for 2025-2027?

(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Newamsterdam Pharma Co Nv's earnings in 2025 is -$192,691,860.On average, 6 Wall Street analysts forecast NAMS's earnings for 2025 to be -$165,000,691, with the lowest NAMS earnings forecast at -$188,089,525, and the highest NAMS earnings forecast at -$140,785,573. On average, 7 Wall Street analysts forecast NAMS's earnings for 2026 to be -$231,856,944, with the lowest NAMS earnings forecast at -$328,875,097, and the highest NAMS earnings forecast at -$173,447,825.

In 2027, NAMS is forecast to generate -$187,717,851 in earnings, with the lowest earnings forecast at -$264,676,876 and the highest earnings forecast at -$93,481,620.

What is NAMS's revenue growth forecast for 2025-2027?

(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 15.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.92%.

Newamsterdam Pharma Co Nv's revenue in 2025 is $74,425,581.On average, 5 Wall Street analysts forecast NAMS's revenue for 2025 to be $2,840,940,225, with the lowest NAMS revenue forecast at $2,421,511,847, and the highest NAMS revenue forecast at $4,315,922,511. On average, 1 Wall Street analysts forecast NAMS's revenue for 2026 to be $40,546,245, with the lowest NAMS revenue forecast at $40,546,245, and the highest NAMS revenue forecast at $40,546,245.

In 2027, NAMS is forecast to generate $14,248,964,107 in revenue, with the lowest revenue forecast at $2,633,253,348 and the highest revenue forecast at $28,321,552,049.

What is NAMS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NAMS) forecast ROA is -9.23%, which is lower than the forecast US Biotechnology industry average of 47.65%.

What is NAMS's Price Target?

According to 6 Wall Street analysts that have issued a 1 year NAMS price target, the average NAMS price target is $40.67, with the highest NAMS stock price forecast at $52.00 and the lowest NAMS stock price forecast at $27.00.

On average, Wall Street analysts predict that Newamsterdam Pharma Co Nv's share price could reach $40.67 by Aug 7, 2026. The average Newamsterdam Pharma Co Nv stock price prediction forecasts a potential upside of 62.21% from the current NAMS share price of $25.07.

What is NAMS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's current Earnings Per Share (EPS) is -$1.88. On average, analysts forecast that NAMS's EPS will be -$1.47 for 2025, with the lowest EPS forecast at -$1.67, and the highest EPS forecast at -$1.25. On average, analysts forecast that NAMS's EPS will be -$2.06 for 2026, with the lowest EPS forecast at -$2.92, and the highest EPS forecast at -$1.54. In 2027, NAMS's EPS is forecast to hit -$1.67 (min: -$2.35, max: -$0.83).

What is NAMS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NAMS) forecast ROE is -9.66%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.